Author of

• 25970

  +

  P3.16 - Treatment of Early Stage/Localized Disease (Not CME Accredited Session) (ID 982)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall

  • 27784

    +

    P3.16-42 - Early Stage Non-Small Cell Lung Cancer Survival in a Chilean Private Teaching Hospital (ID 13512)

    12:00 - 13:30  |  Presenting Author(s): Francisco Suárez
    • Abstract
    • Slides

    Background
    

    Lung cancer is the leading cause of cancer death worldwide. The long-term survival is one the most important outcome for therapies in oncology. In early stages, it permits to adequatly evaluate the quality of the oncological resections of thoracic surgery teams, and in advanced stages it evaluates the quality of the multidisciplinary teams. Screening programs and early diagnosis are the most efficient way to improve survival in lung cancer patients. The results of the surgical treatment in early-stage non-small cell lung cancer of our center is presented.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    All patients treated by our thoracic surgery team for early-stage non-small cell lung cancer, between june 2010 and december 2017, were entered prospectively and consecutively to a web database. Demographic, clinical and pathological data, as well as every adverse event were recorded. All our patients underwent to an exhaustive staging process. Statistical descriptive analysis of clinical and demographic variables and 5 year overall survival by stage are shown.

    4c3880bb027f159e801041b1021e88e8 Result
    

    174 patients were included with median age of 67.7 years old (range 38-86 years), 51.7% female. Adenocarcinoma was the most frequent histology (60.9%). 81% were treated in Stage I and 29% in ​​Stage II.

    For Stage I patients, the median follow-up time was 50 months (IQR: 23.6 - 70.3), and 5-year overall survival 89.79% (95% CI 82.11-94.29). For Stage II patients, the median follow-up time was 33.6 months (IQR: 16.9 - 56.1), and 5-year OS 63.47% (95% CI 33.2-82.91)

    Stage Ia and Ib patients had similar 5y OS: Ia 89.26% (95% CI 80.09-94,35) and Ib 91.3% (95% CI 68.98-97.82)

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    The epidemiological profile of our patients is similar to that published in most of the series, and adenocarcinoma is the main histology in early stage NSCLC in our center.

    5-year overall survival in stage I patients are good compared to other international publications, which we believe is directly related to the exhaustive preoperative and intraoperative study. Correctly assessing the cardiopulmonary capacity of patients allows us to reduce postoperative morbidity and mortality. Accurate staging (imaging, systematic lymph node dissection) allows our group to ensure that stage I patients are actually in stage I, avoiding sub-treating patients who might otherwise require adjuvant therapy.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.